Use of Early Intrathecal Therapy to Manage High-Grade Immune Effector Cell-Associated Neurotoxicity Syndrome

Authors: Joanna Zurko, Bryon D. Johnson, Emilie Aschenbrenner, Timothy S. Fenske, Mehdi Hamadani, Parameswaran Hari, Nirav N. Shah - JAMA Oncology 2022 cited by 39

This case series describes the use of early intrathecal steroid administration to manage high-grade and steroid-refractory immune effector cell-associated neurotoxicity syndrome among patients with B-cell non-Hodgkin lymphoma.